Could combining diabetes drugs early save lives?
NCT ID NCT07465926
First seen Mar 16, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This large study looked at health records from over 450,000 adults with obesity, type 2 diabetes, and early heart or kidney problems. Researchers compared people who added a second drug (either a GLP-1 or SGLT2) within 90 days of starting treatment to those who added a different drug or no extra drug. The goal was to see if early combination therapy was linked to lower death rates and better kidney health over three years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonist and SGLT2 inhibitor
What this could lead to
If the results show benefit, it could support using these drug combinations earlier to reduce death and kidney problems in people with type 2 diabetes and obesity.
What could go wrong
This is an observational study using existing records, not a controlled trial, so it can't prove cause and effect. The findings may be influenced by unmeasured factors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.